News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
421,695 Results
Type
Article (17100)
Company Profile (87)
Press Release (404501)
Multimedia
Podcasts (65)
Webinars (10)
Section
Business (140718)
Career Advice (530)
Deals (21137)
Drug Delivery (53)
Drug Development (36626)
Employer Resources (59)
FDA (9955)
Job Trends (8318)
News (193582)
Policy (14948)
Tag
2027 BioCapital Standard (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Beach Standard (1)
2027 Genetown Standard (3)
2027 Pharm Country Standard (4)
Academia (1438)
Accelerated approval (18)
ADA (17)
Adcomms (2)
Allergies (110)
Alliances (38187)
ALS (67)
Alzheimer's disease (843)
Antibody-drug conjugate (ADC) (346)
Approvals (10449)
Artificial intelligence (638)
ASCO (133)
Autoimmune disease (176)
Automation (57)
Bankruptcy (141)
Best Places to Work (6921)
BIO (39)
BIOSECURE Act (7)
Biosimilars (129)
Biotechnology (74)
Bladder cancer (87)
Brain cancer (42)
Breast cancer (369)
Cancer (3340)
Cardiovascular disease (224)
Career advice (502)
Career pathing (12)
CAR-T (270)
CDC (13)
Celiac Disease (1)
Cell therapy (686)
Cervical cancer (37)
Clinical research (31716)
Collaboration (1804)
Commercialization (1)
Company closure (1)
Compensation (336)
Complete response letters (22)
COVID-19 (1341)
CRISPR (113)
C-suite (822)
Cystic fibrosis (71)
Data (4320)
Decentralized trials (2)
Denatured (29)
Depression (70)
Dermatology (50)
Diabetes (321)
Diagnostics (5658)
Digital health (55)
Diversity (9)
Diversity, equity & inclusion (10)
Drug discovery (270)
Drug pricing (27)
Drug shortages (6)
Duchenne muscular dystrophy (137)
Earnings (46182)
Editorial (13)
Employer branding (12)
Employer resources (56)
Events (59696)
Executive appointments (708)
FDA (12427)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (9)
Frontotemporal dementia (14)
Funding (1261)
Gene editing (227)
Generative AI (48)
Gene therapy (494)
GLP-1 (402)
Government (1537)
Grass and pollen (3)
Guidances (256)
Healthcare (10761)
Hematology (82)
HIV (45)
Huntington's disease (19)
IgA nephropathy (55)
Immunology and inflammation (95)
Immuno-oncology (47)
Indications (115)
Infectious disease (1564)
Inflammatory bowel disease (108)
Inflation Reduction Act (6)
Influenza (102)
Intellectual property (229)
Interviews (70)
IPO (8882)
IRA (11)
Job creations (1680)
Job search strategy (436)
JPM (23)
Kidney cancer (7)
Labor market (27)
Layoffs (158)
Leadership (8)
Legal (3283)
Liver cancer (57)
Longevity (21)
Lung cancer (400)
Lymphoma (306)
Machine learning (51)
Management (20)
Manufacturing (842)
Marketing (4)
MASH (58)
Medical device (12305)
Medtech (12511)
Mergers & acquisitions (13203)
Metabolic disorders (612)
mRNA (181)
Multiple sclerosis (91)
NASH (3)
Neurodegenerative disease (217)
Neuropsychiatric disorders (25)
Neuroscience (1543)
NextGen: Class of 2026 (3778)
Non-profit (1753)
Now hiring (20)
Obesity (203)
Opinion (123)
Ovarian cancer (148)
Pain (163)
Pancreatic cancer (163)
Parkinson's disease (196)
Partnered (23)
Patents (448)
Patient recruitment (443)
Peanut (41)
People (37029)
Pharmaceutical (16)
Pharmacy benefit managers (13)
Phase 1 (11097)
Phase 2 (14033)
Phase 3 (9781)
Pipeline (5926)
Policy (75)
Postmarket research (704)
Preclinical (4808)
Press Release (66)
Prostate cancer (179)
Psychedelics (8)
Radiopharmaceuticals (246)
Rare diseases (519)
Real estate (3820)
Recruiting (29)
Regulatory (13103)
Reports (20)
Research institute (1404)
Resumes & cover letters (80)
Rett syndrome (33)
RNA editing (17)
RSV (53)
Schizophrenia (44)
Series A (235)
Series B (157)
Service/supplier (4)
Sickle cell disease (64)
Special edition (2)
Spinal muscular atrophy (72)
Sponsored (23)
Startups (2723)
State (2)
Stomach cancer (3)
Supply chain (72)
Tariffs (15)
The Weekly (34)
Vaccines (636)
Venture capital (66)
Weight loss (87)
Women's health (81)
Worklife (4)
Date
Today (61)
Last 7 days (252)
Last 30 days (1101)
Last 365 days (16373)
2026 (9621)
2025 (16451)
2024 (20172)
2023 (23775)
2022 (32992)
2021 (34916)
2020 (33286)
2019 (28187)
2018 (21219)
2017 (20654)
2016 (19391)
2015 (22669)
2014 (16965)
2013 (14334)
2012 (15446)
2011 (15791)
2010 (14379)
Location
Africa (386)
Alabama (81)
Alaska (6)
Arizona (241)
Arkansas (12)
Asia (35576)
Australia (5291)
California (7269)
Canada (2267)
China (1076)
Colorado (384)
Connecticut (334)
Delaware (163)
Europe (58718)
Florida (1214)
Georgia (279)
Hawaii (3)
Idaho (34)
Illinois (707)
India (81)
Indiana (344)
Iowa (10)
Japan (513)
Kansas (110)
Kentucky (27)
Louisiana (34)
Maine (28)
Maryland (944)
Massachusetts (4906)
Michigan (338)
Minnesota (527)
Mississippi (5)
Missouri (122)
Montana (29)
Nebraska (17)
Nevada (64)
New Hampshire (89)
New Jersey (2214)
New Mexico (22)
New York (1939)
North Carolina (1009)
North Dakota (10)
Northern California (3241)
Ohio (232)
Oklahoma (21)
Oregon (23)
Pennsylvania (1381)
Puerto Rico (25)
Rhode Island (42)
South America (607)
South Carolina (83)
South Dakota (1)
Southern California (3213)
Tennessee (135)
Texas (1197)
United States (26826)
Utah (264)
Vermont (2)
Virginia (159)
Washington D.C. (19)
Washington State (636)
West Virginia (3)
Wisconsin (121)
Wyoming (1)
421,695 Results for "blue zone technologies ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Cleantech Blue-Zone Technologies Signs Agreement With Class 1
Blue-Zone Technologies Ltd. announced it has signed a definitive collaboration agreement with Class 1 Incorporated, Canada’s leading medical gas and centralized anesthetic capture equipment manufacturer, distributor and service provider.
November 1, 2023
·
3 min read
Cleantech Blue-Zone Technologies Signs Agreement With Respirair Global
Blue-Zone Technologies Ltd. announced it has signed an agreement with Respirair Global LLC to install its patented capture technology in Respirair’s manufacturing facility.
April 11, 2023
·
2 min read
Press Releases
Molecular Targeting Technologies Presents First Clinical Validation of the Evans Blue Platform, Demonstrating Up to 15-Day Tumor Retention Using Approximately 12.5% of the Radioactivity Required for Conventional PRRT
July 7, 2026
·
5 min read
Press Releases
Switchback Medical Signs Lease for 18,000 Square Foot Facility in Costa Rica’s Coyol Free Trade Zone
April 14, 2026
·
3 min read
Mergers & acquisitions
Amgen Makes up to $840M Cancer Play With Dark Blue Takeover
The acquisition is centered on Dark Blue Therapeutics’ small-molecule degrader of the MLLT1 and MLLT3 proteins, which is being tested for acute myeloid leukemia.
January 7, 2026
·
1 min read
·
Tristan Manalac
Blue-Zone Technologies, Ltd. Secures $8 Million of Institutional Financing
Blue-Zone Technologies, Ltd. resulting in the production of branded generic anesthetics, is proud to announce an $8 million round of institutional financing jointly led by the Canadian Venture Capital arm of Crédit Mutuel Equity and Round Pound Ventures, LLC.
October 4, 2022
·
5 min read
Cleantech Blue-Zone Technologies Signs Letter of Intent with Leading Medical Gas Equipment Manufacturer, Class 1Parties consider collaborative agreement for the collection and conversion of anesthetic gases
Blue-Zone Technologies Ltd. announced it has signed a letter of intent with Canada’s leading medical gas equipment manufacturer, distributor and service provider, Class 1 Incorporated.
June 19, 2023
·
3 min read
Press Releases
Blue Earth Therapeutics announces first participant dosed in Phase 1 clinical trial investigating Actinium (²²⁵Ac) rhPSMA-10.1 Injection in metastatic castration-resistant prostate cancer
July 9, 2026
·
6 min read
Press Releases
Canada secures African swine fever zoning arrangement with the Philippines
December 17, 2025
·
4 min read
Press Releases
AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE
January 7, 2026
·
8 min read
1 of 42,170
Next
